Clicky

Xenetic Biosciences, Inc.(XBIO)

Description: Xenetic Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the research and development of certain pharmaceutical products for use in humans that includes the use of the Company's platform technologies that enables the creation of drug therapies primarily for orphan indications. The Company's technologies include PolyXen, Virexxa, OncoHist and ImuXen. The Company is focused primarily on developing its lead product candidates, including ErepoXen, Virexxa and OncoHist, and PolyXen technology. The Company's lead product candidate ErepoXen, a polysialylated form of erythropoietin (EPO) for the treatment of anemia in pre-dialysis patients with chronic kidney disease, and Food and Drug Administration (FDA) orphan designated oncology therapeutics Virexxa and OncoHist for the treatment of progesterone receptor negative endometrial cancer and refractory Acute Myeloid Leukemia, respectively. It is also developing PSA-FVIII.


Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmaceutical Products Pharmacy Dialysis Acute Myeloid Leukemia Kidney Disease Anemia Chronic Kidney Disease FDA Platform Technologies Drug Therapies Growth Factors Endometrial Cancer Erythropoietin Refractory Acute Myeloid Leukemia

Home Page: www.xeneticbio.com

XBIO Technical Analysis

40 Speen Street
Framingham, MA 01701
United States
Phone: 781 778 7720


Officers

Name Title
Mr. Jeffrey F. Eisenberg Esq. CEO, Pres & Director
Mr. James F. Parslow CFO, COO & Corp. Sec.
Dr. Curtis A. Lockshin Chief Scientific Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 0.4335
Price-to-Sales TTM: 3.6145
IPO Date: 2014-06-30
Fiscal Year End: December
Full Time Employees: 4
Back to stocks